What's in Drugs for Neglected Diseases's pipeline?

Drugs for Neglected Diseases has 15 drugs in our index: 3 marketed, 0 filed, 8 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Drugs for Neglected Diseases's portfolio?

Top competitors by shared drug class: Bristol-Myers Squibb, Juan A. Arnaiz, ViiV Healthcare, Banaras Hindu University, Bharat Serums and Vaccines Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/drugs-for-neglected-diseases.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Drugs for Neglected Diseases — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drugs for Neglected Diseases pipeline: 3 marketed, 0 filed, 8 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 8 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Amphotericin B Deoxycholate	Amphotericin B Deoxycholate	marketed	Polyene antifungal	Ergosterol	Infectious Diseases
lopinavir with ritonavir in 1:1 ratio	lopinavir with ritonavir in 1:1 ratio	marketed	HIV protease inhibitor	HIV protease	Infectious Disease
Lopinavir/ritonavir 4:1	Lopinavir/ritonavir 4:1	marketed	HIV protease inhibitor	HIV protease	Infectious Disease
matching placebo of emodepside	matching placebo of emodepside	phase 3
Ambisome + Miltefosine	Ambisome + Miltefosine	phase 3	Antifungal/antiparasitic combination	Ergosterol (amphotericin B); phosphatidylcholine synthesis pathway (miltefosine)	Infectious Disease / Neglected Tropical Diseases
liposomal amphotericin B + paromomycin	liposomal amphotericin B + paromomycin	phase 3	Antifungal/antiparasitic combination	Ergosterol (amphotericin B); ribosomal protein synthesis (paromomycin)	Infectious Disease
LPV/RTV pellets and AZT/3TC or ABC/3TC	LPV/RTV pellets and AZT/3TC or ABC/3TC	phase 3	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase	Infectious Disease / Virology
Miltefosine and Paromomycin	Miltefosine and Paromomycin	phase 3	Antiparasitic combination	Leishmania cell membrane and ribosomal protein synthesis	Infectious Disease / Neglected Tropical Diseases
liposomal amphotericin B + miltefosine	liposomal amphotericin B + miltefosine	phase 3	Antifungal	Ergosterol, Sphingosine N-acyltransferase	Infectious Diseases
Ambisome and Paromomycin	Ambisome and Paromomycin	phase 3	Antifungal and antiparasitic combination	Fungal ergosterol; parasitic 30S ribosomal subunit	Infectious Disease
SSG and Paromomycin sulphate	SSG and Paromomycin sulphate	phase 3	Amino-guanidine and aminoglycoside antibiotic	Ribosome	Infectious Diseases

Therapeutic area mix

Infectious Disease · 4
Infectious Diseases · 3
Infectious Disease / Neglected Tropical Diseases · 2
Infectious Disease / Virology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bristol-Myers Squibb · 2 shared drug classes
Juan A. Arnaiz · 2 shared drug classes
ViiV Healthcare · 2 shared drug classes
Banaras Hindu University · 1 shared drug class
Bharat Serums and Vaccines Limited · 1 shared drug class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 shared drug class
Baqiyatallah Medical Sciences University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Drugs for Neglected Diseases:

Cite this brief

Drug Landscape (2026). Drugs for Neglected Diseases — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/drugs-for-neglected-diseases. Accessed 2026-05-16.